Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The company plans to collaborate with European medical centres to expand adoption of its robotic microsurgery platform
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
Company handles 20,000+ AI-driven calls and chats daily as it scales agentic AI systems across healthcare workflows
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The kidney care provider has established over 40 dialysis centres, delivering more than 40,000 dialysis sessions
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
Subscribe To Our Newsletter & Stay Updated
